NAD+ Dosage Guide: IV, Injection & Oral Protocols Explained
Choosing the right NAD+ dosage depends on your delivery method, research goals, and individual protocol requirements. This guide breaks down clinical dosing frameworks for IV infusion, subcutaneous injection, and oral NMN/NR supplementation — so researchers and clinicians can understand how much NAD+ to take across every major delivery pathway.
What Is NAD+ and Why Does NAD+ Dosage Matter?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell, essential for energy production, DNA repair, and sirtuin activation. As a critical player in cellular metabolism, the role of NAD+ extends from mitochondrial function to oxidative stress defense. Understanding the right NAD+ dosage is fundamental because the compound’s effects depend heavily on how much reaches target tissues — and that varies dramatically by delivery method.
A growing body of research documents a significant decline in NAD+ levels with age. A 2020 review by Braidy and Liu published in Antioxidants & Redox Signaling confirmed that age-related NAD+ depletion correlates with metabolic dysfunction, neurodegeneration, and impaired cellular repair across multiple organ systems.
The Role of NAD+ in Cellular Function
NAD+ serves as an electron carrier in metabolic pathways including glycolysis and the citric acid cycle, directly supporting cellular energy production. Without enough NAD+, cells cannot efficiently convert nutrients into ATP — the molecular fuel that powers virtually every biological process. NAD+ also activates sirtuins, a family of proteins linked to healthy aging, DNA repair, and inflammation regulation.
As documented in a 2018 review by Yoshino et al. in Cell Metabolism , NAD+ metabolism sits at the intersection of energy homeostasis, circadian rhythm regulation, and cellular stress response. This broad functional scope explains the growing interest in NAD+ supplementation and the critical importance of selecting the right dosage for each delivery route.
Why NAD+ Levels Decline With Age
The body’s NAD+ pool shrinks through two concurrent mechanisms: increased consumption by NAD+-dependent enzymes (particularly CD38 and PARPs activated during DNA damage repair) and reduced biosynthesis from precursors like tryptophan, NMN, and NR. This creates a metabolic deficit where cellular NAD+ levels fall below the threshold needed for optimal sirtuin activation, mitochondrial function, and oxidative stress management.
Researchers investigating NAD+ therapy aim to restore intracellular NAD+ concentrations through exogenous supplementation. The dosage per day, the route of administration, and the form of NAD+ used all determine whether supplementation meaningfully raises NAD+ in the tissues that need it most — including skeletal muscle, brain NAD+ pools, and hepatic tissue.
NAD+ Dosage by Delivery Method: IV, Injection & Oral
The optimal dosage of NAD+ varies significantly depending on the route of administration. Each delivery method offers different bioavailability, onset timing, and practical considerations that shape the NAD+ dose protocol selected for a given research application.
NAD+ IV Dosage: 250–500 mg Per Session
NAD+ IV therapy delivers the compound directly into the bloodstream, achieving 100% bioavailability and rapid elevation of blood NAD+ levels. Standard NAD+ IV dosage protocols range from 250 mg to 500 mg per session, with some intensive protocols reaching 750–1,000 mg per session for specific research applications. Infusions typically last 2–4 hours because faster rates can cause chest tightness, nausea, or flushing.
A 2018 analysis published in Cell Metabolism by Rajman et al. confirmed that intravenous NAD+ administration bypasses digestive degradation entirely, delivering the full dose of NAD+ to systemic circulation. Most clinical NAD+ IV therapy protocols schedule sessions one to three times per week during a loading phase, then reduce to monthly or biweekly maintenance.
Subcutaneous NAD+ Injection Dose: 50–200 mg
Subcutaneous injections offer a practical middle ground between IV infusion and oral supplements. The typical NAD+ injection dose ranges from 50 mg to 200 mg per injection, with most protocols calling for subcutaneous injections three times per week. This route avoids the time commitment of IV infusions while still delivering NAD+ with substantially higher bioavailability than oral supplements.
Injection dosage per day varies based on research goals. Some protocols use 100 mg per injection daily during an initial phase, while maintenance protocols typically reduce to 50–100 mg per injection three times per week. Compounded NAD+ for injection must meet strict sterility and purity standards to produce valid research outcomes.
Oral NAD+ Supplements: NMN and NR Dosage
Oral supplements represent the most accessible form of NAD+ supplementation, though the body converts NMN and NR into NAD+ through enzymatic pathways rather than delivering NAD+ directly. NAD+ NMN NR dosage protocols differ because each precursor follows a distinct metabolic route. Standard NMN dosage ranges from 250 mg to 900 mg daily, while NR per day protocols typically range from 300 mg to 1,000 mg daily.
Why Precursor Dosage Differs From Direct NAD+
Oral supplements and IV therapy are not interchangeable on a milligram-for-milligram basis. The body converts NMN and NR into NAD+ through rate-limited enzymatic steps, meaning 500 mg of oral NMN does not produce the same intracellular NAD+ increase as 500 mg of IV NAD+. Research by Airhart et al. (2017) on NR pharmacokinetics demonstrated that oral NR supplementation at 1,000 mg daily for four weeks doubled whole blood NAD+ levels — but tissue-specific distribution varied considerably.
| Delivery Method | Dose Range | Frequency | Bioavailability | Onset |
|---|---|---|---|---|
| IV Infusion | 250–500 mg per session | 1–3× per week (loading); monthly (maintenance) | ~100% | During infusion |
| Subcutaneous Injection | 50–200 mg per injection | 3–5× per week (loading); 2–3× per week (maintenance) | ~85–95% | 30–60 minutes |
| Oral NMN | 250–900 mg daily | Daily | Variable (precursor conversion) | Days to weeks |
| Oral NR | 300–1,000 mg daily | Daily | Variable (precursor conversion) | Days to weeks |
| Nasal Spray | 50–100 mg per spray | 2–3× daily | Moderate (mucosal absorption) | 15–30 minutes |
NAD+ Loading Phase vs. Maintenance Dose Protocols
Most NAD+ dose protocols follow a two-phase structure: an initial NAD+ loading phase designed to rapidly increase NAD+ levels, followed by a reduced NAD+ maintenance dose to sustain elevated concentrations over time. Understanding the distinction between these phases is essential for designing effective research protocols.
What Is a NAD+ Loading Phase?
A loading phase involves higher NAD+ dosage and more frequent administration during the first 1–4 weeks of a protocol. The purpose is to saturate cellular NAD+ pools quickly, overcoming the deficit created by age-related NAD+ decline or other factors that reduce NAD+ availability. During this phase, people tolerate NAD+ differently — some experience flushing, nausea, or fatigue as cellular NAD+ metabolism adjusts.
For IV protocols, a typical loading phase consists of 500 mg per session administered three times per week for 2–4 weeks. Subcutaneous injection loading phases commonly use 100–200 mg per injection daily or five times per week. Oral NMN loading phases may start at 500–900 mg of NMN daily, while NR protocols often begin at 500–1,000 mg daily for four weeks before tapering. A registered clinical trial (NCT03423342) investigating oral NMN supplementation used escalating doses to assess tolerability and NAD+ elevation in human subjects.
Transitioning to a NAD+ Maintenance Dose
After the loading phase, protocols transition to a maintenance dose that sustains elevated levels of NAD+ without the intensity or cost of the loading schedule. Maintenance dosing is typically lower in both mg per dose and frequency. IV maintenance might involve one infusion of 250–500 mg monthly, while subcutaneous maintenance commonly settles at 50–100 mg per injection two to three times per week.
For oral NAD+ supplements, maintenance dosage often drops to 250–500 mg daily of NMN or 300–500 mg daily of NR. The ideal NAD+ maintenance dose depends on individual response, baseline NAD+ levels, and the specific outcomes being measured. Some protocols incorporate periodic “boost” sessions — a brief return to loading-phase dosing — to counter natural NAD+ decline over longer study periods.
Research Protocol Insight
- Loading phases should be time-limited (2–4 weeks) with clear biomarker endpoints to guide transition timing.
- Maintenance protocols vary widely — adjust your dosage based on measured NAD+ levels rather than fixed schedules.
- Consider combining delivery methods (e.g., IV loading with oral maintenance) for sustained NAD+ elevation.
Adjusting Dosage Based on Response
No universal NAD+ dosage chart applies to every individual. Factors including age, baseline cellular NAD+ levels, metabolic rate, and concurrent medications all influence how a person responds to a given dose. Clinicians working with patients starting NAD+ therapy typically begin at the lower end of recommended NAD+ dosage ranges and titrate upward based on tolerability and biomarker response.
Monitoring blood NAD+ levels before and during supplementation provides the most objective measure of protocol effectiveness. Without this data, dosage adjustments rely on subjective markers like mental clarity, energy levels, and exercise recovery — valid indicators but less precise than direct measurement of cellular NAD+ concentrations.
⚠️ 5 Important Research Considerations for NAD+ Dosage
The management of NAD+ supplementation protocols requires careful attention to several research limitations that directly affect safety, efficacy measurement, and reproducibility. benefits of nad+ therapy options can include enhanced energy levels, improved cognitive function, and potential anti-aging effects. As research continues to evolve, it is essential to consider these options within the context of individual health needs and existing medical treatments. This approach will ensure that patients can make informed decisions about incorporating NAD+ therapy into their wellness routines.
- Long-term safety data is limited: Most human trials of NAD+ IV therapy and high-dose oral NMN have followed subjects for 12 weeks or fewer. Long-term effects of sustained higher NAD+ levels remain under investigation.
- Bioavailability varies by individual: Gut microbiome composition, liver enzyme activity, and age all affect how efficiently the body converts NMN or NR into NAD+, making standardized oral dosage charts inherently approximate.
- Purity and source critically affect outcomes: Non-research-grade NAD+ products may contain impurities, degradation products, or incorrect concentrations that compromise study validity and introduce confounding variables.
- Optimal dosage thresholds are not established: The minimum effective dose and the ceiling dose (above which additional NAD+ provides no further benefit) have not been definitively determined for any delivery method in human subjects.
- Interaction with existing medications: NAD+ metabolism intersects with numerous pharmacological pathways. Any patient receiving NAD+ should consult their healthcare provider to screen for potential interactions, particularly with immunosuppressants, chemotherapeutics, and metabolic drugs.
What This Means for Research Validity
Issue: Using consumer-grade NAD+ supplements → Research Impact: Unmeasured impurities and inconsistent concentrations invalidate dose-response data.
Issue: Skipping baseline NAD+ measurement → Research Impact: Impossible to quantify true elevation or attribute outcomes to the intervention.
Issue: Applying fixed dosage without titration → Research Impact: Under- or over-dosing individual subjects reduces statistical power and introduces noise.
“The safety of NAD+ augmentation strategies in humans requires longer-duration clinical trials with standardized dosing, biomarker tracking, and attention to source compound purity.” — Paraphrased from Braidy & Liu, 2020
Sourcing research-grade compounds with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
The following principles emerge from the current body of peer-reviewed research on NAD+ supplementation, spanning in vitro studies, animal models, and early-phase human clinical trials.
The National Institute on Aging (NIA) has highlighted NAD+ metabolism as a promising target for aging research, while noting that translating animal model results to human clinical protocols requires careful dose optimization and long-term safety monitoring.
Researchers who apply these principles consistently report more reproducible biomarker data and clearer dose-response relationships in NAD+ studies.
How to Source High-Quality NAD+ for Your Research
Research-grade NAD+ requires third-party HPLC verification, sterility testing for injectable forms, and a Certificate of Analysis documenting purity above 99%. The form of NAD+ (direct molecule vs. precursor), the supplier’s manufacturing standards, and proper cold-chain storage all determine whether your dosage protocol delivers valid, reproducible results.
Selecting the right NAD+ source is as important as selecting the right dosage. Without verified purity and stability, even the most carefully designed dose protocol can produce unreliable data.
Purity and Third-Party Verification
Research-grade NAD+ should be verified at ≥99% purity via HPLC (High Performance Liquid Chromatography) analysis conducted by an independent third-party laboratory. This verification ensures the compound contains the expected mg per dose without significant degradation products, residual solvents, or contaminants that could confound experimental results.
Many NAD+ supplements on the consumer market lack third-party verification entirely. For research applications, this is a disqualifying gap — unverified NAD+ introduces unmeasured variables into every data point.
Certificate of Analysis and Batch Testing
Every lot of NAD+ used in research should come with a Certificate of Analysis (COA) specific to that production batch. A COA documents the compound’s identity, purity percentage, endotoxin levels (for injectables), moisture content, and heavy metal screening results. Batch-specific testing is non-negotiable because NAD+ stability varies across manufacturing runs.
Researchers should verify that the COA is issued by a laboratory independent of the manufacturer. Internal-only testing creates a conflict of interest that undermines data integrity.
Storage and Handling for Research Compounds
NAD+ is sensitive to heat, light, and moisture. Lyophilized (freeze-dried) NAD+ maintains stability significantly longer than pre-reconstituted solutions. Once reconstituted, NAD+ solutions should be refrigerated at 2–8°C and used within the manufacturer’s recommended timeframe. Improper storage degrades NAD+ into nicotinamide and ADP-ribose, effectively reducing the actual dose delivered regardless of the labeled concentration.
Ready to source research-grade NAD+? Shop Phoenix Peptide Labs’ verified catalog →
Choosing the Right NAD+ Form
Direct NAD+ (for IV and injection) delivers the active molecule without requiring enzymatic conversion. NAD+ precursors like NMN and NR are used in oral supplements because the intact NAD+ molecule has poor oral bioavailability — stomach acid and intestinal enzymes break it down before absorption. The choice between direct NAD+ and NAD+ precursors should be guided by the research question: studies measuring immediate systemic NAD+ elevation typically require IV or injectable forms, while studies on long-term NAD+ repletion may use oral NMN or NR.
Sterility Standards for Injectable NAD+
Any NAD+ intended for subcutaneous or intravenous use must meet USP sterility standards. This includes endotoxin testing (LAL assay), particulate matter testing, and sterility verification through membrane filtration or direct inoculation methods. Compounded NAD+ from non-sterility-tested sources poses contamination risks that can cause injection site reactions, systemic inflammatory responses, or worse.
A 2023 study by Yi et al. published in GeroScience documented that standardized, well-characterized NMN formulations produced consistent NAD+ elevation across subjects — underscoring the link between source quality and research reproducibility.
Phoenix Peptide Labs Quality Assurance
Every NAD+ product ships with batch-specific documentation and meets research-grade standards.
NAD+ Dosage Comparison: Delivery Methods at a Glance
This comparison table consolidates NAD+ dosage ranges, frequency protocols, cost considerations, and practical factors across all major delivery methods. Use it as a reference when selecting the appropriate route for your research design or patient protocol.
| Factor | IV Infusion | Subcutaneous Injection | Oral NMN | Oral NR | Nasal Spray |
|---|---|---|---|---|---|
| Loading Dose | 500 mg, 3×/week | 100–200 mg daily | 500–900 mg daily | 500–1,000 mg daily | 100 mg, 2–3×/day |
| Maintenance Dose | 250–500 mg monthly | 50–100 mg, 2–3×/week | 250–500 mg daily | 300–500 mg daily | 50 mg, 1–2×/day |
| Bioavailability | ~100% | ~85–95% | Variable (precursor) | Variable (precursor) | Moderate |
| Time to NAD+ Elevation | Immediate | 30–60 minutes | Days to weeks | Days to weeks | 15–30 minutes |
| Administration Complexity | High (clinical setting) | Moderate (self-injectable) | Low (capsule/powder) | Low (capsule) | Low (spray device) |
| Sterility Required | Yes — USP standards | Yes — USP standards | No | No | Recommended |
| Common Side Effects | Flushing, nausea, chest tightness | Injection site irritation | Mild GI discomfort | Mild GI discomfort, flushing | Nasal irritation |
| Research Purity Standard | ≥99% HPLC verified | ≥99% HPLC verified | ≥98% recommended | ≥98% recommended | ≥98% recommended |
Who Uses NAD+ Dosage Protocols in Research?
Interest in NAD+ spans multiple research disciplines and clinical applications. The following profiles represent common use cases for structured NAD+ dosage protocols in research and clinical settings.
The Integrative Clinician
A healthcare provider incorporating NAD+ IV therapy or subcutaneous injections into patient protocols for metabolic support and healthy aging research. They need precise mg per session guidelines, verified purity documentation, and clear dosage and frequency frameworks for both loading and maintenance phases.
Have questions about your research needs? Contact our team →
The Independent Researcher Prioritizing Purity
A scientist studying the benefits of NAD+ supplementation on cellular repair, sirtuin activity, or mitochondrial function in controlled laboratory settings. They require research-grade NAD+ with documented purity above 99% to ensure dose-response measurements reflect genuine biological effects rather than contaminant artifacts.
The Wellness Practice Scaling NAD+ Services
A clinical team adding NAD+ therapy to their service offerings, needing to understand the use of NAD+ across IV, injection, and oral pathways to design comprehensive patient programs. They need reliable supply chains for compounded NAD+, clear dosage guides for staff training, and quality assurance that protects both patients and the practice.
Frequently Asked Questions
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that drives energy production and DNA repair. It functions as an electron carrier in metabolic reactions, transferring electrons between molecules during glycolysis, the citric acid cycle, and oxidative phosphorylation.
Beyond energy metabolism, NAD+ activates sirtuins — proteins that regulate inflammation, circadian rhythms, and cellular stress responses linked to healthy aging. Without enough NAD+, these protective pathways operate at reduced capacity, contributing to age-related cellular decline.
For sourcing questions or documentation requests, contact our team.
Standard NAD+ IV dosage protocols range from 250 mg to 500 mg per session, administered over 2–4 hours. During a loading phase, sessions typically occur one to three times per week for 2–4 weeks, then transition to monthly maintenance infusions.
Some intensive research protocols use higher doses up to 750–1,000 mg per session, though infusion rate must be carefully controlled to minimize side effects like flushing, nausea, and chest tightness. Dosage based on individual tolerability is standard clinical practice.
For sourcing questions or documentation requests, contact our team.
Oral NAD+ supplementation typically uses precursors like NMN (250–900 mg daily) or NR (300–1,000 mg daily) rather than direct NAD+. Research by Airhart et al. (2017) showed that 1,000 mg NR daily for four weeks doubled whole blood NAD+ levels.
Most protocols start with a lower dose (250–500 mg daily) for the first week to assess tolerance before increasing. Take NAD+ supplements with food to minimize potential GI discomfort. Consult your healthcare provider before starting any supplementation dosage regimen.
For sourcing questions or documentation requests, contact our team.
A loading phase uses higher doses at greater frequency to rapidly boost NAD+ levels, typically lasting 2–4 weeks. A maintenance dose then sustains those elevated levels at a reduced frequency and lower mg per dose.
For example, an IV loading phase might involve 500 mg three times per week, transitioning to 250–500 mg once monthly for maintenance. Subcutaneous protocols often shift from 100–200 mg daily to 50–100 mg two to three times per week. The transition should be guided by measured biomarkers, not arbitrary timelines.
For sourcing questions or documentation requests, contact our team.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
Most subcutaneous NAD+ injection protocols recommend three to five times per week during a loading phase, reducing to two to three times per week for maintenance. The mg per injection typically ranges from 50 mg to 200 mg depending on the protocol phase.
Injection frequency should be adjusted based on individual response, measured NAD+ levels, and the specific research or clinical objectives. Some patients tolerate daily injections during loading phases, while others require every-other-day scheduling to manage injection site reactions.
For sourcing questions or documentation requests, contact our team.
500 mg is within the standard dosage range for NAD+ IV therapy and is generally well-tolerated when administered at appropriate infusion rates. Side effects at this dose may include temporary flushing, nausea, and chest tightness — typically managed by slowing the infusion rate.
However, most safety data comes from studies lasting 12 weeks or fewer. The long-term safety profile of repeated 500 mg sessions has not been established in large-scale clinical trials. Always work with a healthcare provider when administering NAD+ at any dose.
For sourcing questions or documentation requests, contact our team.
Research-grade NAD+ is verified at ≥99% purity via third-party HPLC testing, with batch-specific Certificates of Analysis documenting identity, purity, endotoxin levels, and heavy metal content. Consumer supplements typically lack this level of verification.
For injectable forms, research-grade NAD+ must also pass USP sterility testing and endotoxin screening — requirements consumer oral supplements do not face. The additional NAD+ quality controls in research-grade products reduce experimental variance and protect research integrity.
For sourcing questions or documentation requests, contact our team.
Yes — multiple clinical studies confirm that oral NMN and NR supplements raise NAD+ levels measurably. A 2023 study by Yi et al. confirmed safe and effective NAD+ elevation with standardized NMN supplementation.
The magnitude of elevation depends on dose, supplement quality, and individual metabolic factors. Oral NAD+ precursors do not achieve the immediate, high-magnitude NAD+ spikes seen with IV therapy, but they support sustained natural NAD+ repletion suitable for longer-term protocols.
For sourcing questions or documentation requests, contact our team.
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human therapeutic use. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use.